a curved stylet and advanced it into an anterolateral branch for stability without helix deployment. During interrogation of the defibrillator lead, however, we found that there were poor R-wave sensing and unacceptably high thresholds and we could not use the quadripolar lead in the MCV for tachycardia sensing.
Hence, we removed the quadripolar lead in the MCV and advanced a bipolar lead (Acuity Steerable 90 cm IS1, Boston Scientific Corp) into the MCV, but we could not advance it to the AIV due to an increase lead caliber. Hence, we advanced it to an anterolateral branch of the CS. We also successfully switched the defibrillator lead to one with a DF1 connection (Endotak Reliance SG 64 cm DF1, Boston Scientific Corp) and readvanced it into another anterolateral branch of the CS. (Figure 2E ,F) The leads were then connected to a generator (Inogen EL ICD, Boston Scientific Corp) with the atrial port plugged.
We then proceeded with defibrillation testing. We made five attempts at induction of ventricular tachyarrhythmia using shock-on-T as well as 50 Hz burst pacing. For three attempts, we did not induce any tachyarrhythmia. For two other attempts, we induced a rapid monomorphic ventricular tachycardia (MMVT) that was nonsustained. We decided not to persist with defibrillation testing. Postprocedure The patient was reviewed in the outpatient clinic 1 month later, and device interrogation showed stable parameters with recorded episodes of nonsustained ventricular tachycardia (NSVT). The patient agreed to repeat defibrillation testing and was readmitted for this. After moderate sedation, rapid MMVT was induced with 50 Hz burst pacing through the device, and an initial programmed defibrillation at 26J degenerated the rhythm into ventricular fibrillation (VF), while the next programmed defibrillation at 41J successfully cardioverted the patient back to ventricular paced rhythm. We reinduced MMVT with 50 Hz burst pacing, and again the first programmed defibrillation at 36J degenerated the rhythm into VF, while the next programmed defibrillation at 41J successfully cardioverted the patient back to ventricular paced rhythm. (Figure 3 ) A long discussion was made with the patient and family, and a decision was made not to pursue with further lead repositionings nor additional defibrillator coils or arrays in a bid to reduce the defibrillation threshold.
| DISCUSSION
Placement of a transvenous right ventricular endocardial pacing wire through a mechanical tricuspid valve is considered a contraindication although there was reported 
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(EGM) showing induction of monomorphic ventricular tachycardia using 50 Hz burst pacing, appropriate detection with no undersensing, appropriate charge time, and delivery of 36J shock which degenerates the rhythm into ventricular fibrillation. This is redetected appropriately, and a delivery of 41J shock successfully cardioverts the patient back to baseline paced rhythm NF FF Marker success previously success. 1 The issues with this approach include prosthetic valve damage, failure, and lead malfunction. Retrospective data suggest that patients who undergo tricuspid valve surgery have an increased risk of conduction disorders requiring cardiac implantable electronic devices, and this risk is doubled with multivalve surgery. 2 In this regard, some centers advocate prophylactic placement of permanent epicardial leads in highrisk patients at the time of surgery. However, epicardial leads may have an increased risk of lead failure and higher thresholds necessitating revisions and frequent generator replacements compared to transvenous systems and this would mean repeat thoracotomies. Our patient had indications for cardiac resynchronization, but we only fulfilled the pacing and defibrillation requirements. The other options we considered were a subcutaneous ICD with a leadless pacemaker but that would involve a large sheath temporarily across the mechanical valve which may risk valve damage. 4 We considered a subcutaneous ICD with a transvenous pacing system in a branch of the CS, but this would involve two incisions with an increased risk of infection and uncertain interactions between the two systems. We also contemplated a completely epicardial system, but the surgical team was reluctant to proceed with a repeat thoracotomy, and furthermore, epicardial systems may have limited longevity as discussed above. Transvenous ICD systems in patients with mechanical tricuspid valves have been achieved in several ways including the use of a floating double-coil in the inferior vena cava (IVC), azygous vein ICD lead implant, the use of a CS defibrillation coil coupled with a left-sided array, and placement of the ICD lead in the low right atrium or MCV. [5] [6] [7] [8] [9] In our patient, the MCV was tortuous, tapering into a small caliber vessel proximally, and we did not have appropriately sized sheaths to assist in the delivery of the ICD lead into the MCV. There have been reports of using more specialized sheaths or smaller ICD leads, but we did not have the luxury of these options.
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Importantly, we did not deploy the ICD lead helix as sensing was already provided by the bipolar pace-sense lead and we wanted to minimize the risk of CS trauma and perforation. We avoided the need for general anesthesia and a repeat thoracotomy in our patient and perhaps mitigated the risks associated with it. However, we were not able to induce a sustained tachyarrhythmia during the procedure for defibrillation testing. When the patient was brought back for defibrillation testing, we were unable to demonstrate any defibrillation safety margin.
The management of a patient with complete heart block, nonischemic cardiomyopathy and mechanical tricuspid valve replacement remains challenging especially in terms of anatomical constraints and high defibrillation thresholds. This case highlights the important considerations in determining the most appropriate device system for such patients and underscores the technical challenges to ensure a safe and successful implantation.
